Intensity-modulated radiation therapy dose prescription and reporting: Sum and substance of the International Commission on Radiation Units and Measurements Report 83 for veterinary medicine.
Carla Rohrer BleyValeria S MeierJuergen BessererUwe SchneiderPublished in: Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association (2019)
Institutions' adherence to protocol, quality assurance, and radiation parameter reporting are key to adequately interpret and compare treatment outcomes in radiation oncology. In 2017, the editorial board for Veterinary Radiology & Ultrasound adapted author guidelines on "technical information for radiation therapy (RT)". These guidelines provide a framework to report the RT treatment process in manuscripts resulting from veterinary clinical trials. In spite of this framework, however, in implementing IMRT, we have identified different "interpretations" of the extended prescription and reporting recommendations of the International Commission on Radiation Units and Measurements (ICRU 83), even within our small team. In the following commentary review, we provide a short summary of various detailed aspects of the ICRU 83 recommended (IMRT) prescription and reporting, including (a) absorbed target dose specification and prescription, (b) homogeneity and conformity, and (c) reporting of absorbed dose in organs at risk. In particular, we want to share our thoughts on possible dangers of noncompliance in adhering to protocol, prescription, and reporting. As veterinary IMRT publications still sparsely adhere to the recommendations of the ICRU, we were motivated to summarize the recommendations to facilitate appropriate reporting for IMRT in future veterinary studies.
Keyphrases
- adverse drug
- radiation therapy
- clinical practice
- clinical trial
- randomized controlled trial
- radiation induced
- magnetic resonance imaging
- type diabetes
- computed tomography
- artificial intelligence
- healthcare
- squamous cell carcinoma
- palliative care
- electronic health record
- metabolic syndrome
- quality improvement
- rectal cancer
- phase ii
- functional connectivity
- combination therapy